en
Scientific article
English

Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial

Published inJournal of clinical oncology, vol. 21, no. 1, p. 66-68
Publication date2003
Abstract

Preclinical studies indicate positive interactions between capecitabine, an oral fluorouracil precursor, and gemcitabine, the current standard treatment for advanced pancreatic carcinoma (APC). In this study, we investigated the addition of capecitabine to gemcitabine treatment for patients with APC.

Keywords
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
  • Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives
  • Female
  • Fluorouracil/analogs & derivatives
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Pancreatic Neoplasms/drug therapy/mortality
  • Survival Rate
  • Switzerland/epidemiology
Citation (ISO format)
HESS, Viviane et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. In: Journal of clinical oncology, 2003, vol. 21, n° 1, p. 66–68.
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0732-183X
469views
0downloads

Technical informations

Creation01/13/2015 1:04:00 PM
First validation01/13/2015 1:04:00 PM
Update time03/14/2023 10:41:21 PM
Status update03/14/2023 10:41:21 PM
Last indexation01/16/2024 3:53:05 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack